Peptide inhibitors for mediating stress responses

Details Peptide inhibitors for mediating stress responses Peptide inhibitors for mediating stress responses

2005-08-23

2011-11-29

Ewoldt, Gerald R (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C530S325000, C530S326000, C530S327000, C530S328000, C530S329000

Reexamination Certificate

active

08067008

ABSTRACT:
The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.

REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5096815 (1992-03-01), Ladner et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5498530 (1996-03-01), Schatz et al.
patent: 5733731 (1998-03-01), Schatz et al.
patent: 5910573 (1999-06-01), Pluckthun et al.
patent: 5922545 (1999-07-01), Mattheakis et al.
patent: 6294353 (2001-09-01), Pack et al.
patent: 6420136 (2002-07-01), Riabowol et al.
patent: 6593353 (2003-07-01), Gudkov et al.
patent: 6630584 (2003-10-01), Solomon et al.
patent: 6723567 (2004-04-01), Harr et al.
patent: 6726895 (2004-04-01), Blankenberg et al.
patent: 2005/0281816 (2005-12-01), Lamping et al.
patent: 2006-505503 (2006-02-01), None
patent: WO 94/12202 (1994-06-01), None
patent: 96/37621 (1996-11-01), None
patent: WO 96/40987 (1996-12-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 98/52558 (1998-11-01), None
patent: WO 98/56416 (1998-12-01), None
patent: WO 99/23091 (1999-05-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 00/23082 (2000-04-01), None
patent: WO 01/01986 (2001-01-01), None
patent: 03/099868 (2003-12-01), None
patent: WO 03/099868 (2003-12-01), None
patent: WO 2006/021954 (2006-03-01), None
Lee, Kon Ho et al., “Peptide recognition by an anti-idiotypic antibody against angiotensin II: Peptide library search for peptides other than angiotensin II”, Biophysical Journal, 68(2 part 2):A406 (1995).
Lomas, M. et al., “Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy”, Annals of Oncology, 15(2):324-329 (2004).
Wang, X. et al., “Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics”, Cancer Chemotherapy and Biological Response Modifiers, 19:309-326 (2001).
Ellis R.E. et al., “Mechanisms and functions of cell death”,Annu Rev Cell Biol.,7:663-698 (1991).
Baker S.J. et al., “Suppression of human colorectal carcinoma cell growth by wild-type p53”,Science,249(4971):912-915 (Aug. 24, 1990).
Lee S. et al., “p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches”,Cell,81(7):1013-1020 (Jun. 30, 1995).
Kastan M.B. et al., “Participation of p53 protein in the cellular response to DNA damage”,Cancer Res.,51(23 Pt 1):6304-6311 (Dec. 1, 1991).
Kuerbitz S.J. et al., “Wild-type p53 is a cell cycle checkpoint determinant following irradiation”,Proc Natl Acad Sci U S A, 89(16):7491-7495 (Aug. 15, 1992).
Yonish-Rouach E. et al., “Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6”,Nature, 352(6333):345-347 (Jul. 25, 1991).
el-Deiry W.S. et al., “Definition of a consensus binding site for p53”,Nat Genet., 1(1):45-49 (Apr. 1992).
Foord O.S. et al., “A DNA binding domain is contained in the C-terminus of wild type p53 protein”,Nucleic Acids Res., 19(19):5191-5198 (Oct. 11, 1991).
Hollstein M. et al., “p53 mutations in human cancers”,Science, 253(5015):49-53 (Jul. 5, 1991).
Ko L.J. et al., “p53: puzzle and paradigm”,Genes Dev., 10(9):1054-1072 (May 1, 1996).
Komarova E.A. et al., “Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors”,Biochem Pharmacol., 62(6):657-67 (May 1, 1996).
Mattson M.P. et al., “Neurodegenerative disorders and ischemic brain diseases”,Apoptosis, 6(1-2):69-81 (Feb.-Apr. 2001).
Martin L.J., “Neuronal cell death in nervous system development, disease, and injury”,Int J Mol Med., 7(5):455-478 (May 2001).
Nickells R.W., “Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death”,Surv Ophthalmol., 43 Suppl 1:S151-S161 (Jun. 1999).
Raghupathi R. et al., “Apoptosis after traumatic brain injury”,J Neurotrauma.17(10):927-938 (Oct. 2000).
Haunstetter A. et al., “Apoptosis: basic mechanisms and implications for cardiovascular disease”,Circ Res., 82(11):1111-1129 (Jun. 15, 1998).
Radic M.Z. et al., “Genetic and structural evidence for antigen selection of anti-DNA antibodies”,Annu Rev Immunol., 12:487-520 (1994).
Pisetsky D.S., “The immunologic properties of DNA”,J Immunol., 156(2):421-423 (Jan. 15, 1996).
Herkel J. et al., “Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA”,Eur J Immunol., 30(4):977-984 (Apr. 2000).
Herkel J. et al., “Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: anti-idiotypes to the anti-p53 antibody are anti-DNA”,Eur J Immunol., 34(12):3623-3632 (Dec. 2004).
Scott J.K. et al., “Searching for peptide ligands with an epitope library”,Science, 249(4967):386-390 (Jul. 27, 1990).
Devlin J.J. et al., “Random peptide libraries: a source of specific protein binding molecules”,Science, 249(4967):404-406 (Jul. 27, 1990).
Cwirla S.E. et al., “Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine”,Science, 276(5319):1696-1699 (Jun. 13, 1997).
Lowman H.B. et al., “Bacteriophage display and discovery of peptide leads for drug development”,Annu Rev Biophys Biomol Struct., 26:401-424 (1997).
Wolf D. et al., “Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene”,Cell, 38(1):119-126 (Aug. 1984).
Nitta M. et al., “Heat shock induces transient p53-dependent cell cycle arrest at Gl/S”,Oncogene, 15(5):561-568 (Jul. 31, 1997).
Takasaki W. et al., “Structure-based design and characterization of exocyclic peptidomimetics tha inhibit TNF alpha binding to its receptor”,Nat Biotechnol, 15(12):1266-1270 (Nov. 1997).
Roberts R.W. et al., “RNA-peptide fusions for the in vitro selection of peptides and proteins”,Pro Natl Acad Sci U S A., 94(23):12297-12302 (Nov. 11, 1997).
Wells J.A. et al., “Rapid evolution of peptide and protein binding properties in vitro”,Curr Opin Biotechnol., 3(4):355-362 (Aug. 1992).
Dedman J.R. et al., “Selection of targeted biological modifiers from a bacteriophage library of random peptides. The identification of novel calmodulin regulatory peptides”,J Biol Chem., 268(31):23025-23030 (Nov. 5, 1993).
Wilson D.R. et al., “Phage display: applications, innovations, and issues in phage and host biology”,Can J Microbiol, 44(4):313-329 (Apr. 1998).
Van Regenmortel M.H. et al., “D-peptides as immunogens and diagnostic reagents”,Curr Opin Biotechnol,9(4):377-382 (Aug. 1998).
Thompson C.B. et al., “Apoptosis in the pathogenesis and treatment of disease”,Science, 267(5203):1456-1462 (Mar. 10, 1995).
Nicoletti I. et al., “A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry”,J Immunol Methods, 139(2):271-279 (Jun. 3, 1991).
Gavrieli Y. et al., “Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation”,J Cell Biol, 119(3):493-501 (Nov. 1992).
Crameri et al., “A-Geneseq—8 Accession No. ADM57310”, Jul. 1, 2004.
Nathan C., “Points of control in inflammation”,Nature, 420(6917):846-852 (Dec. 19-26, 2002).
Cohen I.R., “Discrimination and dialogue in the immune system”,Semin Immunol,12(3):215-219 (Jun. 2000).
Dinarello C.A., &#

Affiliated with

Also associated with

Rating

Peptide inhibitors for mediating stress responses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide inhibitors for mediating stress responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitors for mediating stress responses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4271664